TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
FTRE

Fortrea Holdings Inc.

Healthcare · Biotechnology

18.10$ +3.1% vs. previous close Closing price · As of: Aug 19, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Fortrea Holdings Inc. (FTRE). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — FTRE
Segment 2021 2022 2023 2024 2025
Clinical Services $2.76B 90.4% $2.84B 100.0% · +2.7% $2.84B 100.0% · +0.2% $2.70B 100.0% · -5.1% $2.72B 100.0% · +1.0%
Enabling Services $294.0M 9.6%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Revenue by region

Revenue by region — FTRE
Segment 2021 2022 2023 2024 2025
North America $1.65B 54.0% $1.42B 49.9% · -14.2% $1.40B 49.2% · -1.2% $1.27B 47.1% · -9.2% $1.29B 47.4% · +1.6%
Europe $868.4M 28.4% $841.9M 29.7% · -3.1% $827.5M 29.1% · -1.7% $800.0M 29.7% · -3.3% $851.7M 31.3% · +6.5%
Other $539.5M 17.6% $579.6M 20.4% · +7.4% $616.6M 21.7% · +6.4% $626.9M 23.2% · +1.7% $582.1M 21.4% · -7.1%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 19, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?